4周维持ICS-福莫特罗对新诊断轻度哮喘的成人:对症状、肺功能和炎症的影响

IF 4.6 2区 医学 Q1 ALLERGY
Yan Zhou, Xue Zhang, Zichong Xu, Jinwen Wang, Yilin Pan, Yingying Zhang, Xue Tian, Yuning Huang, Chengjian Lv, Qi Zheng, Wuping Bao, Min Zhang
{"title":"4周维持ICS-福莫特罗对新诊断轻度哮喘的成人:对症状、肺功能和炎症的影响","authors":"Yan Zhou, Xue Zhang, Zichong Xu, Jinwen Wang, Yilin Pan, Yingying Zhang, Xue Tian, Yuning Huang, Chengjian Lv, Qi Zheng, Wuping Bao, Min Zhang","doi":"10.1007/s11882-025-01217-6","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>This study aimed to determine whether patients with newly diagnosed mild asthma benefit more from initiating treatment with maintenance inhaled corticosteroids (ICS) plus formoterol versus ICS alone. We compared the effects of these two 4-week maintenance strategies on asthma control, lung function, and airway inflammation.</p><p><strong>Recent findings: </strong>Recent evidence supports the effectiveness of as-needed ICS-formoterol in mild asthma management. However, data on initial short-term maintenance strategies remain limited. Most studies focus on long-term outcomes or symptom-driven therapy, with little insight into the early phase and its impact on inflammation and lung function. Notably, GINA 2024 emphasizes that \"mild asthma\" is a retrospective label and may not reliably guide the selection of the appropriate initial treatment step. Even in so-called mild asthma, severe outcomes may occur, highlighting the need for early, objective assessment to guide treatment decisions. In this retrospective analysis of two prospective studies including 128 patients with newly diagnosed mild asthma, both the ICS-formoterol and ICS groups showed improvements in asthma control, lung function, and airway inflammation. However, the ICS-formoterol group achieved significantly greater improvements in Asthma Control Test scores, Asthma Control Questionnaire scores, large airway function (FEV<sub>1</sub>, FEV<sub>1</sub>/FVC), small airway function, and eosinophil reduction, particularly in patients with baseline small airway dysfunction. FEV<sub>1</sub> reversibility in baseline bronchodilation test was positively correlated with improvements in FEV<sub>1</sub>, FEV<sub>1</sub>/FVC, and eosinophil count reduction in the ICS-formoterol group. These findings support 4-week ICS-formoterol maintenance therapy as an effective initial strategy in mild asthma, with reassessment guiding longer-term management.</p>","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":"25 1","pages":"40"},"PeriodicalIF":4.6000,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"4-Week Maintenance ICS-Formoterol versus ICS in Adults Newly Diagnosed Mild Asthma: Effects on Symptoms, Lung Function, and Inflammation.\",\"authors\":\"Yan Zhou, Xue Zhang, Zichong Xu, Jinwen Wang, Yilin Pan, Yingying Zhang, Xue Tian, Yuning Huang, Chengjian Lv, Qi Zheng, Wuping Bao, Min Zhang\",\"doi\":\"10.1007/s11882-025-01217-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose of review: </strong>This study aimed to determine whether patients with newly diagnosed mild asthma benefit more from initiating treatment with maintenance inhaled corticosteroids (ICS) plus formoterol versus ICS alone. We compared the effects of these two 4-week maintenance strategies on asthma control, lung function, and airway inflammation.</p><p><strong>Recent findings: </strong>Recent evidence supports the effectiveness of as-needed ICS-formoterol in mild asthma management. However, data on initial short-term maintenance strategies remain limited. Most studies focus on long-term outcomes or symptom-driven therapy, with little insight into the early phase and its impact on inflammation and lung function. Notably, GINA 2024 emphasizes that \\\"mild asthma\\\" is a retrospective label and may not reliably guide the selection of the appropriate initial treatment step. Even in so-called mild asthma, severe outcomes may occur, highlighting the need for early, objective assessment to guide treatment decisions. In this retrospective analysis of two prospective studies including 128 patients with newly diagnosed mild asthma, both the ICS-formoterol and ICS groups showed improvements in asthma control, lung function, and airway inflammation. However, the ICS-formoterol group achieved significantly greater improvements in Asthma Control Test scores, Asthma Control Questionnaire scores, large airway function (FEV<sub>1</sub>, FEV<sub>1</sub>/FVC), small airway function, and eosinophil reduction, particularly in patients with baseline small airway dysfunction. FEV<sub>1</sub> reversibility in baseline bronchodilation test was positively correlated with improvements in FEV<sub>1</sub>, FEV<sub>1</sub>/FVC, and eosinophil count reduction in the ICS-formoterol group. These findings support 4-week ICS-formoterol maintenance therapy as an effective initial strategy in mild asthma, with reassessment guiding longer-term management.</p>\",\"PeriodicalId\":55198,\"journal\":{\"name\":\"Current Allergy and Asthma Reports\",\"volume\":\"25 1\",\"pages\":\"40\"},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2025-09-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Allergy and Asthma Reports\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s11882-025-01217-6\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Allergy and Asthma Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11882-025-01217-6","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

摘要

回顾目的:本研究旨在确定新诊断的轻度哮喘患者是否从开始使用维持性吸入皮质类固醇(ICS)加福莫特罗治疗比单独使用ICS治疗获益更多。我们比较了这两种4周维持策略对哮喘控制、肺功能和气道炎症的影响。最近的发现:最近的证据支持按需使用ics -福莫特罗治疗轻度哮喘的有效性。然而,关于初期短期维护策略的数据仍然有限。大多数研究关注的是长期结果或症状驱动疗法,很少关注早期阶段及其对炎症和肺功能的影响。值得注意的是,GINA 2024强调“轻度哮喘”是一个回顾性标签,可能无法可靠地指导选择适当的初始治疗步骤。即使在所谓的轻度哮喘中,也可能发生严重的后果,这突出了早期客观评估以指导治疗决策的必要性。本研究回顾性分析了两项前瞻性研究,包括128例新诊断的轻度哮喘患者,ICS-福莫特罗组和ICS组均显示哮喘控制、肺功能和气道炎症得到改善。然而,ics -福莫特罗组在哮喘控制测试评分、哮喘控制问卷评分、大气道功能(FEV1、FEV1/FVC)、小气道功能和嗜酸性粒细胞减少方面取得了显著更大的改善,特别是在基线小气道功能障碍患者中。基线支气管扩张试验中FEV1可逆性与ICS-formoterol组FEV1、FEV1/FVC改善和嗜酸性粒细胞计数减少呈正相关。这些发现支持4周的ics -福莫特罗维持治疗作为轻度哮喘的有效初始策略,重新评估指导长期管理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
4-Week Maintenance ICS-Formoterol versus ICS in Adults Newly Diagnosed Mild Asthma: Effects on Symptoms, Lung Function, and Inflammation.

Purpose of review: This study aimed to determine whether patients with newly diagnosed mild asthma benefit more from initiating treatment with maintenance inhaled corticosteroids (ICS) plus formoterol versus ICS alone. We compared the effects of these two 4-week maintenance strategies on asthma control, lung function, and airway inflammation.

Recent findings: Recent evidence supports the effectiveness of as-needed ICS-formoterol in mild asthma management. However, data on initial short-term maintenance strategies remain limited. Most studies focus on long-term outcomes or symptom-driven therapy, with little insight into the early phase and its impact on inflammation and lung function. Notably, GINA 2024 emphasizes that "mild asthma" is a retrospective label and may not reliably guide the selection of the appropriate initial treatment step. Even in so-called mild asthma, severe outcomes may occur, highlighting the need for early, objective assessment to guide treatment decisions. In this retrospective analysis of two prospective studies including 128 patients with newly diagnosed mild asthma, both the ICS-formoterol and ICS groups showed improvements in asthma control, lung function, and airway inflammation. However, the ICS-formoterol group achieved significantly greater improvements in Asthma Control Test scores, Asthma Control Questionnaire scores, large airway function (FEV1, FEV1/FVC), small airway function, and eosinophil reduction, particularly in patients with baseline small airway dysfunction. FEV1 reversibility in baseline bronchodilation test was positively correlated with improvements in FEV1, FEV1/FVC, and eosinophil count reduction in the ICS-formoterol group. These findings support 4-week ICS-formoterol maintenance therapy as an effective initial strategy in mild asthma, with reassessment guiding longer-term management.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
11.20
自引率
1.80%
发文量
21
审稿时长
6-12 weeks
期刊介绍: The aim of Current Allergy and Asthma Reports is to systematically provide the views of highly selected experts on current advances in the fields of allergy and asthma and highlight the most important papers recently published. All reviews are intended to facilitate the understanding of new advances in science for better diagnosis, treatment, and prevention of allergy and asthma. We accomplish this aim by appointing international experts in major subject areas across the discipline to review select topics emphasizing recent developments and highlighting important new papers and emerging concepts. We also provide commentaries from well-known figures in the field, and an Editorial Board of internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research. Over a one- to two-year period, readers are updated on all the major advances in allergy and asthma.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信